Back Bay Life Science Report
26 episodes - English - Latest episode: 12 days ago - ★★★★★ - 2 ratingsBack Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
The Current Dynamics in Capital Markets
April 15, 2024 20:01 - 22 minutes - 30.9 MBWelcome to another episode with the DNB//Back Bay Partnership for Healthcare. In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment Banking at Back Bay Life Science Advisors, to talk about current market dynamics and the 2024 IPO outlook in the US and in Europe. Topic...
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
March 18, 2024 18:46 - 37 minutes - 51.7 MBGuests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections. In this episode resident immunologist Dr. Pete Bak and Christian Thienel discuss vaccine technology, up-and-coming areas of interest, such as RSV, and th...
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
February 14, 2024 17:37 - 25 minutes - 35.6 MBA Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian Thienel Length: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our opinions and perspectives on these topics. Our team has written these whitepapers to address industry interest: The Radiopharmaceuti...
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
January 03, 2024 02:02 - 25 minutes - 35 MBAs we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology. In this episode: CRISPR and Vertex’s approval of Exa-cel, the first CRISPR-based genetic medicine approved by the FDA in the US The m...
Monthly Roundup of News from Healthcare Development
November 07, 2023 18:38 - 30 minutes - 41.4 MBIn our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area. In this next installment of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors talk about kidney disease and the various aspects of the ...
The Current and Future Landscape of Healthcare IPO Markets
October 27, 2023 18:28 - 23 minutes - 32.6 MBwith the DNB//Back Bay Partnership for Healthcare In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public this year, including Schott Pharma, Germany’s largest IPO earlier this year. In the first podcast episode with the DNB//Back Bay Partn...
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
October 12, 2023 20:53 - 24 minutes - 34 MBA conversation on the rising trends in the cardiology space Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology. During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the i...
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
August 29, 2023 06:00 - 25 minutes - 35.6 MBIn this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including: Background information on the class of therapeutics known as ADCs, which have been on the market since 2000 The number of headlines around ADCs lately, especially the standing ov...
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
April 14, 2023 23:31 - 29 minutes - 40 MBThe world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of care while reducing healthcare costs. In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler sp...
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
February 09, 2023 07:00 - 28 minutes - 67 MBFor biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting. In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more ...
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
January 24, 2023 01:52 - 37 minutes - 87.3 MBIn our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald progress in health and human care. Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Miche...
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
September 19, 2022 23:19 - 28 minutes - 38.7 MBFor biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something lik...
The Promising Field of Targeted Protein Degraders (TPDs)
July 30, 2022 16:50 - 23 minutes - 31.9 MBwith Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra Nasir Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture funding and partnerships surrounding TPDs. Read Dr. Nasir's article "From drug target inhibition to degradation: a TACtical strategy" here. Topics in this podcast ...
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
July 06, 2022 14:50 - 29 minutes - 40.9 MBThis is the first episode in our podcast series of Q&As on biopharma and medtech development—directly from active developers. Our podcast listeners, including Back Bay clients, have submitted timely and relevant questions about life science development and the daily challenges they face. Christian Thieniel and Brendan Wang, two senior members of the Back Bay Life Science Advisors team with a tremendous amount of experience in the life sciences, especially as it relates to scientifi...
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
May 19, 2022 14:51 - 29 minutes - 40.9 MBIn this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Department of Clinical Immunology at Odense University Hospital in Denmark and a research fellow at the University of Southern Denmark, to discuss current perspectives—clinical, scientific and manufacturing—on the cell therapy space. Dr. Barnkob’s expertise spans basic and clinical immunology, with a particular interest in advanced cellular ...
The Evolving Regulatory Framework for Novel Medicines in the EU
April 25, 2022 15:43 - 25 minutes - 35.6 MBBiopharma companies looking to establish a footprint in Europe face country-specific decision-making processes. The health technology assessments (HTAs) in France and Germany, for example, look very different. Does this regional level of thinking make it easier or potentially more difficult to get medicines to market and into the hands of patients who need them? In this episode of Back Bay’s Life Science podcast, Pete Bak is joined by Alexander Natz, Secretary-General of the Europ...
The Commercial Potential of Optogenetic Therapies
March 15, 2022 02:42 - 23 minutes - 32 MBFifteen years ago, scientists discovered optogenetics, a technique of using light to stimulate light-sensitive receptors in order to turn brain cells “on” and “off" at the flip of a switch. Advances in optogenetics have allowed this technology to move from the laboratory to humans, and more recently biopharma companies have been quick to incorporate optogenetic therapies into their ophthalmology portfolios. In this episode of Back Bay’s Life Science Report, Peter Bak is joined by K...
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
January 19, 2022 06:00 - 22 minutes - 30.5 MBAntibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments possible, but what happens when bacteria or other microorganisms become resistant to the drugs we use against them? Back Bay Life Science Advisors’ Managing Director Peter Bak sits down with Marc Lemonnier, a molecular and cellular microbiologist and CEO of Antabio, a clinical stage company located in France developing novel antibiotic therapies, ...
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
January 07, 2022 12:00 - 25 minutes - 35.6 MBDespite the heavy influx of capital over the past years, medtech or biopharma sell-side assignments can still be ripe with challenges. In this episode of Back Bay’s industry podcast, Back Bay Life Science Advisors’ investment banking team discuss best practices for successful sell-side licensing, partnering, and M&A, including: Best practices for readying vital aspects of deal preparation Identifying deal issues, red flags ahead of time Articulation of the path forward, includi...
Cell and Gene Therapy Investment Trends
November 22, 2021 19:21 - 19 minutes - 26.9 MBCell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear their discussion on emerging investment themes and which ones were key topics of discussion at this year’s conference. Topics include: ...
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
October 13, 2021 19:28 - 26 minutes - 36.5 MB“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.” - Jonathan P. Gertler, MD For years, biotech has been the dominant theme in life sciences development, offering a great deal in treatment advances and in terms of investing versatility and returns potential. But with promising system solutions serving broader swaths of patients, medtech is resurging. Medtech investment has grown dramatical...
Remote Patient Monitoring
August 05, 2021 04:00 - 26 minutes - 36.9 MBOne of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. Just ahead of the pandemic, investment in patient monitoring was booming; priming the system for quick uptake and innovation. As with vaccines, much groundwork had been done to prepare for dramatic innovation and widespread, rapid patient use, seemingly “overnight.” In this episode of Back Bay Life Science Advisors' industry podcast, Drs. Jonathan Gertler a...
New Drug Pricing and Market Access
June 30, 2021 18:50 - 26 minutes - 36.8 MBIn this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisors to discuss how pharmaceutical companies price their drugs. They cover the ins and outs of health economics, how payers make sense of a high price, and ways this varies around the globe. With a focus on Biogen’s recent Aduhelm approval, the discussion includes how Biogen likely went about price setting and how this aligns with ICER...
The Question of Investment in Antimicrobials
June 11, 2021 05:10 - 25 minutes - 35.4 MBIn this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article in STAT News and to talk about the world of anti-infectives. Dr. Bak has more than ten years of expertise in infection and treatment. He began his research at Dartmouth Medical School and later continued at MIT, where he was an American Cancer Society Postdoctoral Fellow at the Koch Institute of Integrative Cancer Re...
Life Science SPACs: A Forward Look at this Evolving Asset Class
June 03, 2021 04:00 - 25 minutes - 35.2 MBWelcome to Episode #2 of The Life Science Report. In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs). The feeling surrounding healthcare SPACs right now is almost...giddy. With enormous capital flowing into the biotech sector, SPACs have emerged as one of the hottest financing options. Last year...
Gene Therapies: What’s to Come as The Industry Moves Forward
June 02, 2021 04:00 - 21 minutes - 30.5 MBWelcome to Episode 1 of The Life Science Report. In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life Science Advisors to discuss the field of gene therapies and insights from their recently authored piece in Cell & Gene, “The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers),” and their newly released white paper on BBLSA.com. Gene therapy has been talked about for many years, and it’s only in the past few ...